Making It Possible
Making It Possible
In-Office Pupil Dilation
Estimated US Market Size: $250M
Post Ocular Surgery Pain and Inflammation
Estimated US Market Size $400M
*Commercial Partnership with Formosa Pharmaceuticals
Pediatric Myopia
Estimated US Market Size $5.0B
*Outlicensed in Asia
We are creating transformative therapies currently being studied for use in progressive myopia, presbyopia, and mydriasis. We believe that our innovation in ophthalmic delivery will change the way eyecare professionals and patients view eye medications. Eyenovia strives to create ophthalmic drug delivery technologies that are more effective, safer, and smarter than traditional eyedroppers. Our Optejet® dispenser is designed to deliver minimal amounts of medication to the eye, horizontally, while maintaining similar efficacy to traditional eyedropper treatment. The Optejet® has the potential to come equipped with Bluetooth capability, to help track patient compliance and adherence more easily.
We envision the Optejet®’s technology being utilized for additional applications and drug therapies. Reduction in systemic exposure and toxicity with the Optejet®’s microdosing, compared to a traditional eyedropper, could mean the dispenser may have a better tolerability and safety profile than existing topical treatments. For therapies where adherence is vital to treatment success, the Optejet® may assist with patient compliance.
Eyenovia Announces Changes to the Board of Directors
NEW YORK, Feb. 07, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPâ„¢) therapeutics, today announced changes to its Board of Directors. Dr. Sean Ianchulev, Director, Chief Executive Officer and Chief Medical Officer of Eyenovia, has been appointed Chairman Kenneth Lee, Jr., Director, has been named Lead Director Rachel […]